Your World, Fully Explored.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Pope Leo XIV
Pope Francis
Mother's Day
Catholic Church
Vatican
World War II
Donald Trump
Conclave
Motorsports
Social Media
Artificial Intelligence
US Politics
Published • loading... • Updated

GSK awaits Nucala decision after FDA target date passes

Summary by Endpoints News
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to Endpoints News.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Endpoints NewsEndpoints News

GSK awaits Nucala decision after FDA target date passes

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to Endpoints News.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Thursday, May 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal